Precision for Medicine Acquires ACT Oncology         

ACT Oncology is very pleased to announce the promotion of Jeff Seroskie to Corporate Vice President.

Jeff has been instrumental in driving ACT Oncology’s growth and success since he joined the company in 2005. His strong leadership, strategic vision and overall performance have resulted in the award of several important programs.  Jeff’s outstanding operational expertise and steadfast commitment to providing exceptional service continue to drive ACT Oncology’s phenomenal repeat business rate.     Notably, within the last two years, Jeff successfully created and implemented ACT Oncology’s Project Management infrastructure, enhancing our use of standard processes and methodologies across studies and increasing the consistency of our operational performance.  The results of these efforts have been particularly noticeable in the conduct of several global programs involving CRO partners.   Jeff also developed ACT Oncology’s employee mentorship program, focused on training and developing key competencies to enhance career opportunities for our employees.

In his new role, in addition to overseeing the Project Management Function, Jeff will be responsible for managing the execution and delivery of all clinical trials to ensure the highest quality service to ACT Oncology’s growing client base.  He will also oversee global governance for trials involving our European partners and will confirm resourcing for new Requests for Proposals and new project wins.     As part of the Corporate Committee, Jeff will have direct input into evaluating and setting strategic priorities and will help lead company growth initiatives, including global CRO partnerships.

We're changing our name and website to reflect our exciting new capabilities since joining Precision for Medicine. Please visit us at precisionforoncology.com to see how we’re delivering the next generation of CRO services for oncology innovators.